October 19, 2021
TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference
October 14, 2021
WHO Global Tuberculosis Report—New Drugs and Regimens Need to be Combined with Equitable and Universal Access
Statement by Mel Spigelman, MD, President and Chief Executive Officer, TB Alliance September 30, 2021
TB Alliance Welcomes New Board Members
Dr. Eric Goosby, Sundar Kodiyalam, David Y. Norton, and Sangita Reddy Join Board September 6, 2021
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
August 19, 2021
TB Alliance Convenes Community Engagement Stakeholders to Discuss Clinical Trial Updates
During a virtual forum on August 12, 2021 speakers shared experiences and updates on engaging with communities for research and development programs July 15, 2021
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development
The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium July 14, 2021
TB Alliance Welcomes Dr. Suvanand Sahu to the Access Advisory Committee
He will bring more than 20 years of global and country level experience in TB and a people-centered approach to his role on the committee June 29, 2021
TB Alliance Congratulates Dr. Dan Everitt on Career Transition
As Chief Medical Officer, Dr. Everitt played key role in advancing TB therapy April 15, 2021